vs
Side-by-side financial comparison of Alkermes plc. (ALKS) and NOVO NORDISK A S (NVO), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $384.5M | — | ||
| Q3 25 | $394.2M | — | ||
| Q2 25 | $390.7M | — | ||
| Q1 25 | $306.5M | — | ||
| Q4 24 | $430.0M | — | ||
| Q3 24 | $378.1M | — | ||
| Q2 24 | $399.1M | — | ||
| Q1 24 | $350.4M | — |
| Q4 25 | $49.3M | — | ||
| Q3 25 | $82.8M | — | ||
| Q2 25 | $87.1M | — | ||
| Q1 25 | $22.5M | — | ||
| Q4 24 | $146.5M | — | ||
| Q3 24 | $92.4M | — | ||
| Q2 24 | $91.4M | — | ||
| Q1 24 | $36.8M | — |
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
| Q4 25 | 15.1% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 37.8% | — | ||
| Q3 24 | 27.7% | — | ||
| Q2 24 | 27.5% | — | ||
| Q1 24 | 12.4% | — |
| Q4 25 | 12.8% | — | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | 22.3% | — | ||
| Q1 25 | 7.3% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 22.9% | — | ||
| Q1 24 | 10.5% | — |
| Q4 25 | $0.29 | — | ||
| Q3 25 | $0.49 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $0.88 | — | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $0.53 | — | ||
| Q1 24 | $0.21 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
